ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EMMA Emmaus Life Sciences Inc

2.77
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Emmaus Life Sciences Inc NASDAQ:EMMA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.77 2.75 2.87 0 01:00:00

Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum March 26th

23/03/2020 12:35pm

GlobeNewswire Inc.


Emmaus Life Sciences (NASDAQ:EMMA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Emmaus Life Sciences Charts.

Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, today announced that Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer, and Jay Sherwood, Chief Financial Officer, will present live at LifeSciencesInvestorForum.com on March 26th.

DATE: March 26, 2020  TIME: 11:00am ETLINK: https://tinyurl.com/032620LSIF

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.lifesciencesinvestorforum.com.

About Emmaus Life SciencesEmmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Its FDA-approved Endari® (prescription grade L-glutamine oral powder) is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. For more information, please visit www.emmausmedical.com.

About Life Sciences Investor ForumLife Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.

A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

CONTACTS:Emmaus Life Sciences, Inc.Joseph (Jay) C. Sherwood IIIChief Financial Officer(310) 214-0065, Ext. 3005jsherwood@emmauslifesciences.com

Life Sciences Investor ForumJohn M. ViglottiSVP Corporate Services, Investor Access(212) 220-2221johnv@lifesciencesinvestorforum.com

1 Year Emmaus Life Sciences Chart

1 Year Emmaus Life Sciences Chart

1 Month Emmaus Life Sciences Chart

1 Month Emmaus Life Sciences Chart

Your Recent History

Delayed Upgrade Clock